Product Elements:
Glucagon glucagon sterile water sterile water water water glucagon glucagon glucagon hydrochloride glucagon hydrochloric acid sodium hydroxide lactose monohydrate anhydrous lactose
Drug Interactions:
7 drug interactions 7.1 drug interactions
Indications and Usage:
1 indications & usage 1.1 severe hypoglycemia glucagon for injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes. 1.2 diagnostic aid glucagon for injection is indicated as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
Warnings and Cautions:
5 warnings and precautions 5.1 catecholamine release in patients with pheochromocytoma glucagon for injection is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor [see contraindications ( 4 )]. if the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure. 5.2 hypoglycemia in patients with insulinoma in patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, glucagon for injection administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. glucagon for injection is contraindicated in patients with insulinoma [see contraindications ( 4 )]. if a patient develops symptoms of
Read more...hypoglycemia after a dose of glucagon for injection, give glucose orally or intravenously. 5.3 hypersensitivity and allergic reactions allergic reactions have been reported with glucagon, these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. glucagon for injection is contraindicated in patients with a prior hypersensitivity reaction [see contraindications ( 4 )]. 5.4 lack of efficacy in patients with decreased hepatic glycogen glucagon for injection is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for glucagon for injection administration to be effective. patients with these conditions should be treated with glucose. 5.5 necrolytic migratory erythema necrolytic migratory erythema (nme), a skin rash commonly associated with glucagonomas (glucagonproducing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported postmarketing following continuous glucagon infusion. nme lesions may affect the face, groin, perineum and legs or be more widespread. in the reported cases nme resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. should nme occur, consider whether the benefits of continuous glucagon infusion outweigh the risks. 5.6 hyperglycemia in patients with diabetes mellitus when used as a diagnostic aid treatment with glucagon for injection in patients with diabetes mellitus may cause hyperglycemia. monitor diabetic patients for changes in blood glucose levels during treatment and treat if indicated. 5.7 blood pressure and heart rate increase in patients with cardiac disease when used as a diagnostic aid glucagon for injection may increase myocardial oxygen demand, blood pressure, and pulse rate which may be life-threatening in patients with cardiac disease. cardiac monitoring is recommended in patients with cardiac disease during use of glucagon for injection as a diagnostic aid, and an increase in blood pressure and pulse rate may require therapy. 5.8 hypoglycemia in patients with glucagonoma glucagon administered to patients with glucagonoma may cause secondary hypoglycemia. glucagon for injection is contraindicated in patients with glucagonoma when used as a diagnostic aid [see contraindications ( 4 )]. test patients suspected of having glucagonoma for blood levels of glucagon prior to treatment, and monitor for changes in blood glucose levels during treatment. if a patient develops symptoms of hypoglycemia after a dose of glucagon for injection, give glucose orally or intravenously.
Dosage and Administration:
2 dosage & administration 2.1 important administration instructions for using the glucagon emergency kit for low blood sugar to treat severe hypoglycemia glucagon for injection is for subcutaneous, intramuscular, or intravenous injection. administer intravenously only under medical supervision. instruct patients and their caregivers on the signs and symptoms of severe hypoglycemia. because severe hypoglycemia requires the help of others to recover, instruct the patient to inform those around them about glucagon for injection and its instructions for use. administer glucagon for injection as soon as possible when severe hypoglycemia is recognized. instruct the patient or caregiver to read the instructions for use at the time they receive a prescription for glucagon for injection. emphasize the following instructions to the patient or caregiver: using the supplied prefilled syringe, carefully insert the needle through the rubber stopper of the vial containing glucagon for injection powde
Read more...r and inject all the liquid from the syringe into the vial. shake the vial gently until the powder is completely dissolved and no particles remain in the fluid. the reconstituted solution should be clear and colorless. inspect visually for particulate matter and discoloration. if the resulting solution is cloudy or contains particulate matter do not use. the reconstituted solution is 1 mg per ml glucagon. immediately after reconstitution, inject the solution subcutaneously or intramuscularly in the upper arm, thigh, or buttocks. in addition, healthcare providers may administer intravenously. call for emergency assistance immediately after administering the dose. when the patient has responded to the treatment and is able to swallow, give oral carbohydrates to restore the liver glycogen and prevent recurrence of hypoglycemia. discard any unused portion. 2.2 dosage in adults and pediatric patients for using the glucagon emergency kit for low blood sugar to treat severe hypoglycemia adults and pediatric patients weighing more than 25 kg or for pediatric patients with unknown weight 6 years and older the recommended dosage is 1 mg (1 ml) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously. if there has been no response after 15 minutes, an additional 1 mg dose (1 ml) of glucagon for injection may be administered using a new kit while waiting for emergency assistance. pediatric patients weighing less than 25 kg or for pediatric patients with unknown weight less than 6 years of age the recommended dosage is 0.5 mg (0.5 ml) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously. if there has been no response after 15 minutes, an additional 0.5 mg dose (0.5 ml) of glucagon for injection may be administered using a new kit while waiting for emergency assistance. 2.3 important administration instruction for using glucagon for injection diagnostic kit and glucagon for injection single-dose vial as a diagnostic aid reconstitute glucagon for injection with 1 ml of sterile water for injection. using a syringe, withdraw all of the sterile water for injection (if supplied) or 1 ml sterile water for injection and inject into the glucagon for injection vial. shake the vial gently until the powder is completely dissolved and no particles remain in the fluid. the reconstituted fluid should be clear and colorless. inspect visually for particulate matter and discoloration. if the resulting solution is cloudy or contains particulate matter do not use. the reconstituted solution is 1 mg per ml glucagon. immediately after reconstitution, inject the solution intravenously or intramuscularly into upper arm, thigh, or buttocks. discard any unused portion. after the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure. 2.4 dosage in adults for using glucagon for injection diagnostic kit and glucagon for injection single-dose vial as a diagnostic aid the recommended diagnostic dose for relaxation of the stomach, duodenal bulb, duodenum, and small bowel is 0.2 mg to 0.5 mg administered intravenously or 1 mg administered intramuscularly; the recommended dose to relax the colon is 0.5 mg to 0.75 mg administered intravenously or 1 mg to 2 mg administered intramuscularly [see clinical pharmacology ( 12- 12.2)]. the onset of action after an injection will depend on the organ under examination and route of administration [see clinical pharmacology ( 12- 12.2)].
Dosage Forms and Strength:
3 dosage forms & strengths glucagon for injection is a white lyophilized powder supplied as follows: treatment of severe hypoglycemia 1 mg single-dose vial of glucagon for injection with a 1 ml single-dose syringe of sterile water for injection, usp (glucagon emergency kit for low blood sugar) use as a diagnostic aid 1 mg single-dose vial of glucagon for injection 1 mg single-dose vial of glucagon for injection with a 1 ml single-dose vial of sterile water for injection, usp (diagnostic kit)
Contraindications:
4 contraindications glucagon for injection is contraindicated in patients with: pheochromocytoma [see warnings and precautions ( 5- 5.1)] insulinoma [see warnings and precautions ( 5- 5.2)] because of the risk of hypoglycemia known hypersensitivity to glucagon or any of the excipients in glucagon for injection. allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension [see warnings and precautions ( 5- 5.3)] glucagonoma [see warnings and precautions ( 5- 5.8)] because of risk of hypoglycemia when used as a diagnostic aid
Adverse Reactions:
6 adverse reactions the following important adverse reactions are described below and elsewhere in the labeling: hypersensitivity and allergic reactions [see warnings and precautions ( 5- 5.3)] necrolytic migratory erythema [see warnings and precautions ( 5- 5.5)] hyperglycemia in patients with diabetes mellitus when used as a diagnostic aid [see warnings and precautions ( 5- 5.6)] blood pressure and heart rate increase in patients with cardiac disease when used as a diagnostic aid [see warnings and precautions ( 5- 5.7)] 6.1 clinical studies experience because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in clinical trials of another drug and may not reflect the rates observed in practice. in a randomized single-blind clinical study of glucagon for injection, 29 healthy subjects received a single dose of 1 mg glucagon for injection intramuscularly. table 1 shows
Read more...the most common adverse reactions that were not present at baseline and occurred in at least 5% of patients. table 1: adverse reactions occurring in ⥠5% of healthy subjects who received glucagon for injection intramuscularly other adverse reactions hypertension and tachycardia have occurred with glucagon treatment. 6.2 postmarketing experience additional adverse reactions have been identified during post-approval use of glucagon. because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. hypoglycemia and hypoglycemic coma. patients taking indomethacin may be more likely to experience hypoglycemia following glucagon administration [see drug interactions ( 7 )]. necrolytic migratory erythema (nme) cases have been reported postmarketing in patients receiving continuous infusion of glucagon. adverse
Drug Interactions:
7 drug interactions 7.1 drug interactions
Use in Specific Population:
8 use in specific populations 8.1 pregnancy risk summary available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation. in rat and rabbit reproduction studies, no embryofetal toxicity was observed with glucagon administered by injection during the period of organogenesis at doses representing up to 100 and 200 times the human dose, respectively, based on body surface area (mg/m2) (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respe
Read more...ctively. data animal data in rats and rabbits given glucagon by injection at doses of 0.4, 2.0, and 10 mg/kg (up to 100 and 200 times the human dose based on mg/m2 for rats and rabbits, respectively) there was no evidence of increased malformations or embryofetal lethality. 8.2 lactation risk summary there is no information available on the presence of glucagon in human or animal milk, the effects of glucagon on the breastfed child or the effects of glucagon on milk production. however, glucagon is a peptide and would be expected to be broken down to its constituent amino acids in the infant's digestive tract and is therefore, unlikely to cause harm to an exposed infant. 8.4 pediatric use the safety and effectiveness of glucagon for injection for the treatment of severe hypoglycemia in pediatric patients with diabetes have been established. safety and effectiveness for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in pediatric patients have not been established.
Overdosage:
10 overdosage if overdosage occurs, the patient may experience nausea, vomiting, inhibition of gi tract motility, increase in blood pressure and pulse rate. in case of suspected overdosing, the serum potassium may decrease and should be monitored and corrected if needed. if the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.
Description:
11 description glucagon is an antihypoglycemic agent and a gastrointestinal motility inhibitor. it is produced by solid phase peptide synthesis. the chemical structure of the glucagon is identical to human glucagon. glucagon is a single-chain polypeptide containing 29 amino acid residues. the structure of glucagon is: glucagon for injection is a sterile, lyophilized white powder in a 3 ml vial for subcutaneous, intramuscular or intravenous use. the reconstituted solution contains glucagon as hydrochloride 1 mg per ml and lactose monohydrate (107 mg). glucagon for injection is supplied at ph 2.5 to 3.5 and is soluble in water. description
Clinical Pharmacology:
12 clinical pharmacology 12.1 mechanism of action glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. extrahepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon. 12.2 pharmacodynamics treatment of severe hypoglycemia blood glucose concentration rises within 10 minutes of injection and maximal concentrations are attained at approximately 30 minutes after injection (see figure 1). the duration of hyperglycemic action after intravenous or intramuscular injection is 60 to 90 minutes. in a study in healthy subjects, a subcutaneous dose of 1 mg glucagon for injection resulted on average a peak blood glucose concentration of 79.3 mg/dl with a median time of 50 minutes after injection. 12.3 pharmacokinetics absorption following
Read more... subcutaneous administration of glucagon for injection, the median time to reach the maximum baseline uncorrected plasma glucagon concentrations of 3533 pg/ml was approximately 10 to 13 minutes after dosing following intramuscular administration of 1 mg dose, the maximum baseline uncorrected plasma glucagon concentrations of 3391 pg/ml were attained approximately 10 minutes after dosing. elimination the mean apparent half-life of glucagon was about 42 minutes after subcutaneous administration. the mean apparent half-life of glucagon was 26 minutes after intramuscular administration. metabolism glucagon is degraded in the liver, kidney, and plasma. clinical
Nonclinical Toxicology:
13 nonclinical toxicology 13.1 carcinogenesis, mutagenesis, impairment of fertility carcinogenesis long term studies in animals to evaluate carcinogenic potential have not been performed. mutagenesis synthetic glucagon was negative in the bacterial reverse mutation assay (ames test). the clastogenic potential of synthetic glucagon in the chinese hamster ovary (cho) assay was positive in the absence of metabolic activation. doses of 100 and 200 mg/kg of glucagon of both pancreatic and recombinant origins gave slightly higher incidences of micronucleus formation in male mice but there was no effect in females. the weight of evidence indicates that synthetic and recombinant glucagon are not different and do not pose a genotoxic risk to humans. impairment of fertility glucagon was not tested in animal fertility studies. studies in rats have shown that pancreatic glucagon does not cause impaired fertility.
How Supplied:
16 how supplied/storage & handeling glucagon emergency kit for low blood sugaris supplied in the following dosage forms. ndc 51662-1498-1 glucagon emergency kit for low blood sugar 1 mg glucagon in 1 ml. 1 ml single-dose vial of glucagon for injection with 1 ml single-dose syringe of sterile water for injection, usp for reconstitution hf acquisition co llc, dba healthfirst mukilteo, wa 98275 also supplied in the following manufacture supplied dosage forms 16.1 how supplied glucagon for injection is supplied as a sterile, lyophilized white powder available as follows: 16.2 recommended storage before reconstitution the package containing glucagon for injection vials may be stored up to 24 months at 20° to 25° c (68° to 77° f) [see usp controlled room temperature] prior to reconstitution. do not freeze. keep in the original package to protect from light. after reconstitution use reconstituted glucagon solution immediately. discard any unused portion [see dosage and administrat
Read more...ion (2.3)]. how supplied
Package Label Principal Display Panel:
Principal display panel - serialized kit labeling 51662-1498-1 serialized kit labeling
Principal display panel - kit label kit label
Principal display panel - vial label vial label
Principal display panel - syringe label syringe label
Principal display panel - kit contents and interior labeling kit contents and interior labeling